Five-Year Sales for Newly Marketed Prescription Drugs With and Without Initial Orphan Drug Act Designation-Reference-Cited by-同舟云学术

Five-Year Sales for Newly Marketed Prescription Drugs With and Without Initial Orphan Drug Act Designation

Published:2023-05-09 Issue:18 Volume:329 Page:1607
ISSN:0098-7484
Container-title:JAMA
language:en
Short-container-title:JAMA

Author:

Tu S. Sean¹,Nagar Sarosh²,Kesselheim Aaron S.²,Lu Zhigang²,Rome Benjamin N.²

Affiliation:

1. West Virginia University College of Law, Morgantown

2. Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women’s Hospital, Boston, Massachusetts

Abstract

This study evaluates sales revenue earned in the first 5 years for newly marketed brand-name drugs with and without an initial orphan drug designation.

Publisher

American Medical Association (AMA)

Subject

General Medicine

Link

https://jamanetwork.com/journals/jama/articlepdf/2804613/jama_tu_2023_ld_230022_1682951025.54103.pdf

Reference5 articles.

1. Spending for orphan indications among top-selling orphan drugs approved to treat common diseases.;Chua;Health Aff (Millwood),2021

2. FDA approval and regulation of pharmaceuticals, 1983-2018.;Darrow;JAMA,2020

3. Trends in prescription drug launch prices, 2008-2021.;Rome;JAMA,2022

4. Reforming the Orphan Drug Act for the 21st century.;Sarpatwari;N Engl J Med,2019

5. Pearson? SD, Dreitlein? WB, Henshall? C. Indication-Specific Pricing of Pharmaceuticals in the United States Health Care System. Institute for Clinical and Economic Review. Published March 2016. Accessed January 20, 2023. https://icerorg.wpengine.com/wp-content/uploads/2020/11/Final-Report-2015-ICER-Policy-Summit-on-Indication-specific-Pricing-March-2016_revised-icons-002.pdf

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical Benefit and Revenues of Drugs Affected by Rare Pediatric Disease Priority Review Vouchers, 2017-2023;The Journal of Pediatrics;2024-12

2. Four Decades of Orphan Drugs and Priorities for the Future;New England Journal of Medicine;2024-07-11

3. Three Pillars of Support for Orphan Drug Programs: Individual Valuations, Societal Valuations, and Anonymous Altruism;Value in Health;2024-07

4. Partial Orphan Cancer Drugs: US Food and Drug Administration Approval, Clinical Benefit, Trials, Epidemiology, Price, Beneficiaries, and Spending;Value in Health;2024-04

5. Gaucher Disease: A Glance from a Medicinal Chemistry Perspective;ChemMedChem;2024-03-08